<?xml version="1.0" encoding="UTF-8"?>
<p id="p0060">The 21st Century Cures Act established a new expedited option for certain eligible biologic products, the designation of Regenerative Medicine Advanced Therapy, as well as a Breakthrough Devices program.
 <xref rid="bib21" ref-type="bibr">
  <sup>21</sup>
 </xref> Gene and cell therapy products recently approved include onasemnogene abeparvovec-xioi for patients with spinal muscular atrophy, and talimogene laherparepvec for patients with recurrent melanoma. There was a cumulative total of 17 approvals for all gene and cell therapy products given the Regenerative Medicine Advanced Therapy designation by the FDA's Center for Biologics Evaluation and Research through December 2019.
 <xref rid="bib22" ref-type="bibr">
  <sup>22</sup>
 </xref>
</p>
